Evidence-based coverage of GLP-1 agonists, metabolic peptides, and weight loss science for Australian adults.
57 articles · sorted by most recent
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. What ATTAIN-1 and ACHIEVE-1 show on weight loss and Australia.
An evidence-based guide to natural weight loss in Australia: caloric balance, diet, exercise, sleep, hormones, GLP-1 medications, and peptide science.
The SELECT trial showed semaglutide cut MACE by 20% in non-diabetic patients with obesity and CV disease. Mechanisms, findings, and Australian PBS access.
Emerging research on GLP-1 receptor agonists and alcohol cravings: 2025 RCT data, the reward-pathway mechanism, and what it means for semaglutide users.
Comparing bariatric surgery and GLP-1 medications on efficacy, durability, cost, and risk in Australia today, plus a practical decision framework for 2026.
A research overview of how recombinant HGH (somatropin) activates the growth hormone receptor and JAK2/STAT5 signalling to drive hepatic IGF-1 production.
A research-backed explainer on orforglipron (Foundayo), the first oral GLP-1 agonist for weight loss — dosing, ATTAIN trial data, and injectable comparison.
A detailed breakdown of TRIUMPH-1 Phase 3 results for retatrutide, the triple-hormone agonist that achieved up to 25% mean weight loss at 80 weeks in the trial.
Cagrilintide is a long-acting amylin analog; Cagrisema pairs it with semaglutide. Here's what REDEFINE data, amylin co-agonism, and Australia's path mean.
Is body recomposition possible? Yes, under specific conditions. Here's the science of losing fat and building muscle at once, with protein and training needs.
Why weight loss plateaus happen: adaptive thermogenesis, NEAT decline, leptin changes, the Biggest Loser study, and strategies to break through.
Sub-clinical GLP-1 microdosing is rising on cost grounds. Here's what STEP 1 titration data, SURMOUNT-1, and Australia's supply context actually show.
Men over 50 face hormonal and metabolic changes that make conventional weight loss advice ineffective. This protocol addresses testosterone and sarcopenia.
A deep dive into the evidence behind HIIT for weight loss — EPOC, appetite effects, insulin sensitivity, and protocols for beginners through advanced.
Compounded semaglutide in Australia: why the TGA banned compounding in 2024, the safety concerns behind it, current legal status, and approved 2026 alternatives.
A science-based overview of AOD-9604, Tesamorelin, and Semaglutide — how each compound works, what research shows, and the Australian regulatory context.
STEP 1 extension data shows roughly two-thirds of lost weight returns within a year of stopping semaglutide. Why regain happens and how to maintain it.
Liraglutide (Saxenda) and semaglutide (Wegovy) are both PBS-listed GLP-1 agonists for weight management. A comparison of efficacy, side effects, and cost.
Australia obesity statistics 2026: 2 in 3 adults overweight or obese, 1 in 4 children affected, $11.8B economic cost, trends since 1995 and GLP-1 era context.
Understand the science of Zone 2 cardio: fat oxidation, mitochondrial adaptation, metabolic health gains, and how much low-intensity training you need weekly.
Menopause weight gain is driven by hormonal and metabolic shifts, not simply ageing. What the evidence says about oestrogen, GLP-1 medications, and MHT.
Complete guide to Ozempic (semaglutide) in Australia 2026: PBS listing status, cost with and without subsidy, access, supply issues, and Wegovy comparison.
A science-based guide to carb cycling for weight loss — how it works, the main protocols, macro calculations, and how it compares to keto and fasting.
A comprehensive guide to tirzepatide (Mounjaro) in Australia — TGA approval, PBS status, prescription costs, SURMOUNT results, and semaglutide comparison.
Tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy) are both GLP-1 agonists for weight loss, but work differently. What SURMOUNT and STEP trials show.
Facial volume loss and skin laxity on GLP-1 medications is real, but not unique to Ozempic. Here's what drives it and how to reduce the effect.
A deep dive into the foods, nutrients, and factors that stimulate endogenous GLP-1 release — the science behind 'natural Ozempic' claims, and a daily protocol.
Decades of diet wars have produced a clear answer, and it's not what either side claims. What the best head-to-head trials show about low-carb vs low-fat.
An evidence-based guide to protein intake for weight loss — grams per kilogram, timing, satiety mechanisms, and Australian context, from 2024-2026 research.
Why the standard calorie deficit stops working after 40 for women — perimenopause hormones, metabolic adaptation, cortisol-driven fat storage, and a fix.
Everything you need to know about caloric deficit for weight loss — TDEE calculation, safe rate of loss, metabolic adaptation, and protein-sparing strategies.
A detailed comparison of tirzepatide vs semaglutide in Australia — SURMOUNT and SUSTAIN trial data, TGA status, PBS eligibility, cost, and who it suits.
Can food and supplements really mimic Ozempic's GLP-1 effects? The Stanford 2026 discovery, berberine, and fibre, weighed against 'natural ozempic' claims.
Why PCOS makes weight loss harder and what research shows works — insulin resistance, low-GI diet, inositol, metformin, GLP-1s, and PCOS-specific exercise.
Nausea, vomiting, constipation, and fatigue affect up to 40% of GLP-1 users in the first weeks. What causes them and the strategies that keep you on treatment.
An Australian guide to cortisol-driven belly fat: HPA axis physiology, why visceral fat responds to stress hormones, testing options, and a reset protocol.
Cortisol and weight gain are closely linked through fat storage, appetite disruption, and insulin resistance. The science, and how to lower cortisol naturally.
A research-backed review of intermittent fasting for weight loss — 16:8, 5:2, and time-restricted eating weighed against the latest Cochrane meta-analysis.
How thyroid dysfunction causes weight gain in Australia: TSH levels, Hashimoto's, subclinical hypothyroidism, diet strategies, and PBS medication options.
What insulin resistance is, how to test for it, and the strategies that reverse it — diet, exercise, supplements, and medications for sustainable results.
Bariatric surgery outcomes are shaped by pre-operative preparation. Evidence on liver-shrinkage diets, nutritional optimisation, exercise, and pathways.
Your gut microbiome shapes how many calories you extract from food, how much fat you store, and how hunger hormones work. Evidence on restoring diversity.
Wegovy (semaglutide 2.4mg) has been recommended for PBS listing in Australia for chronic weight management. What the decision means for cost and access.
Up to 40% of weight lost on GLP-1 drugs like Ozempic and Wegovy can be lean mass. The evidence-based protocol for resistance training, protein, and care.
Protein is the most important macronutrient for weight loss — not just muscle preservation, but satiety and thermic effect. What trials show about targets.
Wegovy's 2025 PBS listing was a watershed moment for obesity medicine. Which GLP-1 medications are PBS-listed, eligibility, cost, and pending PBAC changes.
Starvation mode, spot reduction, eating after 8pm — most weight loss advice is myth, not evidence. What research actually shows about fat loss results.
Visceral fat, the fat around your organs, is metabolically active, drives inflammation, and predicts cardiovascular risk better than BMI. What evidence says.
Poor sleep increases hunger hormones, reduces satiety signals, and drives cravings for high-calorie foods. The evidence on sleep's role in weight control.
A research review of NAD+ and its role in metabolic regulation and energy production, and whether evidence supports a role in weight loss, sirtuins, AMPK.
A research-backed look at diet, exercise, and nutrients that stimulate natural GLP-1 secretion, and how they compare to pharmaceutical GLP-1 agonists.
A clear explanation of what insulin resistance is, how it develops, why it drives weight gain, and how research shows it can be reversed, GLP-1s included.
A research review of HGH Fragment 176-191, the growth hormone fragment studied for lipolytic effects — mechanism, animal data, and limited human evidence.
A research overview of AOD-9604, the HGH Fragment 176-191 peptide studied for lipolytic action — origins, mechanism, trial history, and regulatory status.
A clear explanation of how GLP-1 receptor agonists reduce appetite, promote weight loss, and affect blood sugar, explained without unnecessary complexity.
A comparison of the three leading incretin-based weight loss compounds — semaglutide, tirzepatide, retatrutide — on mechanism, trial data, and outlook.
A research-backed analysis of STEP-1 trial data on lean mass changes with semaglutide, and what it means for the narrative around GLP-1s and muscle loss.